Sixth Street provided a $500 million non-dilutive term loan financing facility for Biohaven Pharmaceuticals.
The Sixth Street term loan facility will be available to Biohaven under the following terms:
- Up to $500 million in a structured term loan facility. Biohaven will use the proceeds for the development, promotion and commercial launch of NURTEC ODT, as well as for general corporate purposes of the company and its subsidiaries.
- $375 million is immediately available to Biohaven upon closing.
- An additional $125 million is committed and available when net sales of NURTEC ODT (rimegepant) reach $45 million during either Q2/21 or Q2/21.
“Sixth Street is one of the top capital provider partners of choice with deep expertise and understanding of the pharmaceutical sector,” Vlad Coric, MD, CEO of Biohaven, said. “The fully committed debt facility from Sixth Street flexibly increases our cash position at an attractive cost and reflects the confidence that our partners have drawn from the strong launch and commercial progress of Nurtec ODT. With Sixth Street’s broad platform and track record of providing differentiated, creative financing solutions, we look forward to the potential of expanding our relationship with future growth of Nurtec ODT sales and upcoming clinical development milestones across our pipeline.”
“The impressive launch of Nurtec ODT underscores the paradigm shift that is occurring with CGRP-targeting therapies in the treatment of migraine and Sixth Street is pleased to provide Biohaven with the financing to help the company deliver this important new medication to patients around the globe,” Vijay Mohan, partner; Adam Kaye, managing director; and Jeff Pootoolal, managing director at Sixth Street, said in a joint statement. “The impressive launch metrics achieved with Nurtec ODT to date and Biohaven’s broad pipeline of late-stage assets gave us the confidence to engage the company in offering long-term capital to enable their growth.”
Cooley acted as legal advisor to Biohaven on the transaction. Latham & Watkins and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo acted as legal advisors to Sixth Street.
Biohaven is a biopharmaceutical company focused on the development and commercialization of therapies to improve the lives of patients with neurological and neuropsychiatric diseases. Biohaven’s portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraines.
Sixth Street is a global investment firm with more than $34 billion in assets under management and committed capital.